Phoenix Rising tells QMUL: release the PACE trial data
Mark Berry, Acting CEO of Phoenix Rising, presents the Board of Directors’ open letter to Queen Mary University of London (QMUL) urging them to release the PACE trial data, and hopes that other non-UK organisations will join British charities in the same request...
Discuss the article on the Forums.

Anti-EBV Drug Under Development at Wistar Institute

Discussion in 'Latest ME/CFS Research' started by Gemini, Jul 13, 2015.

  1. Gemini

    Gemini Senior Member

    Wistar Institute researchers homing in on a novel anti-EBV drug that disables the EBNA1 protein received a three-year $5.6 million grant from the U.K. based Wellcome Trust...

    Targeting EBV related cancers, researchers believe it may also have value for diseases like MS and mono.

    They've met with the FDA to discuss the design of human trials expected to begin in 2018.

    If initial trials succeed they'll look for a pharmaceutical company to underwrite final trials.

    Sounds encouraging...

See more popular forum discussions.

Share This Page